BIO vs TNDM · rev $651.0M vs rev $501.8M
BIO (BIO) versus Tandem Diabetes Care Inc (TNDM) — a side-by-side from cached financials, not a winner call.
BIO (BIO) common stock.
Tandem Diabetes Care Inc (TNDM) is a medical devices company listed on NASDAQ.
Latest reported BIO revenue for 2026-06-30 was $651.0M. Net income was $371.4M. Revenue was up 9.9% from 2026-03-31 to 2026-06-30. BIO currently screens at market cap $0.
Latest reported TNDM revenue for 2026-06-30 was $501.8M. Net income was -$41.6M. TNDM currently screens at market cap $1.06B.
BIO currently screens at market cap $0. TNDM currently screens at market cap $1.06B.
Not investment advice. Open the BIO and TNDM stock pages for the full models.
Not investment advice.